ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, announces that JETREA (ocriplasmin) has gained approval in Brazil.
JETREA has been indicated for the treatment of adults with vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.
If left untreated, VMT generally leads to significant visual distortion, deterioration in visual acuity, or even central blindness. With JETREA® , retina physicians in Brazil will have access to the world’s first and only pharmacological treatment option for VMT, allowing them to intervene earlier and potentially stop the progression of this debilitating disease.
ThromboGenics’ partner Alcon, which is commercializing JETREA® outside the US, will be responsible for the launch of the drug in Brazil.
About JETREA (ocriplasmin)
JETREA (ocriplasmin) is a truncated form of human plasmin. In the US, JETREA® is indicated for the treatment of symptomatic VMA. In Europe, JETREA® is indicated for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. JETREA® is a selective proteolytic enzyme that cleaves fibronectin, laminin and collagen, three major components of the vitreoretinal interface that play an important role in vitreomacular adhesion.
JETREA has been evaluated in two multi-center, randomized, double-masked Phase III trials
Irregular heartbeats Nausea Chest pain fainting Male viagra online buy http://www.unica-web.com/archive/letter_of_the_president9812.htm impotence is a result of affected physical and psychological health. You may need to take public viagra ordering on line transportation, spend money on your parent site. Generics are often introduced in Canada several years before but only few people are familiar of this with good service viagra sans prescription its use for aging men. Just as people are professional viagra seeking solutions for healthy weight loss, they are also seeking advice about how to deal with the situation. conducted in the U.S. and Europe involving 652 patients with vitreomacular adhesion. Both studies
met the primary endpoint of resolution of VMA at day 28.
JETREA’s Phase III program found that 26.5% of patients treated with ocriplasmin saw resolution of
VMA, compared with 10.1% of patients receiving placebo (p<0.01). The Phase III program also
showed that JETREA was generally well tolerated with most adverse events being transient and mild
in severity.